A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Summary

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Eligibility

Age range

18+ years

Sex

Female

Healthy volunteers

No

Interventions

• Biological
  Sacituzumab tirumotecan

  IV Infusion

• Biological
  Bevacizumab

  IV Infusion

• Drug
  H1 receptor antagonist

  Rescue medication taken per approved product label before sacituzumab tirumotecan

• Drug
  H2 receptor antagonist

  Rescue medication taken per approved product label before sacituzumab tirumotecan

• Drug
  Acetaminophen (or equivalent)

  Rescue medication taken per approved product label before sacituzumab tirumotecan

• Drug
  Dexamethasone (or equivalent)

  Rescue medication taken per approved product label before sacituzumab tirumotecan

Locations (167)